Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2022-02-22 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
独立董事关于第三届董事会第六次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is an opinion statement from independent directors regarding a specific agenda item for a board meeting, specifically about increasing the 2022 daily related-party transaction limits. It references compliance with regulatory rules and company bylaws, and it is a pre-approval or endorsement of a board meeting agenda item. This type of document is related to board or management information rather than a financial report, audit, or regulatory filing. It does not contain financial statements or earnings data, nor is it a notice or announcement of voting results. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on governance and board meeting matters, supporting this classification.
2022-02-22 Chinese
第三届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the sixth meeting of the third board of directors of Shenzhen BGI Genomics Co., Ltd. It details the meeting date, attendance, agenda, and voting results on increasing the 2022 daily related-party transaction limit. It includes references to independent directors' opinions and related announcements but does not contain financial statements or detailed management discussion. The document is a formal announcement of board decisions rather than a full management report or annual report. Therefore, it fits best under Board/Management Information (MANG). The document length is short (1029 characters), and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2022-02-22 Chinese
中信证券股份有限公司关于深圳华大基因股份有限公司增加2022年度日常关联交易预计额度的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the increase in the 2022 annual expected amount of daily related-party transactions for Shenzhen BGI Genomics Co., Ltd. It includes descriptions of the related-party transactions, their necessity, pricing policies, independent directors' opinions, supervisory board opinions, and the sponsor's verification opinion. The document is regulatory in nature, related to compliance with stock exchange rules and internal governance, but it is not a financial report, earnings release, or management discussion. It is not a short announcement but a formal verification opinion document. This type of document fits best under Regulatory Filings (RNS) as it is a compliance and regulatory disclosure that does not fit other specific categories like Annual Report, Interim Report, or Capital Update.
2022-02-22 Chinese
独立董事关于第三届董事会第六次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding a board meeting decision about increasing the 2022 annual expected amount for related party transactions. It references compliance with stock exchange listing rules and company bylaws. The content focuses on board meeting matters and independent director opinions rather than financial results or audit reports. It is not a full annual report, audit report, earnings release, or regulatory filing. The document is related to board/management information, specifically about board meeting decisions and independent director opinions on those decisions.
2022-02-22 Chinese
第三届监事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Shenzhen BGI Genomics Co., Ltd. It details the meeting convening, attendance, and the approval of an agenda item related to increasing the 2022 annual related-party transaction limit. The document is an official announcement of a board/committee meeting decision rather than a full report or financial statement. It does not contain financial statements or detailed financial analysis, nor is it a regulatory filing or certification. It fits best under Board/Management Information (MANG) as it relates to internal governance decisions and board resolutions.
2022-02-22 Chinese
国浩律师（深圳）事务所关于深圳华大基因股份有限公司二〇二二年第一次临时股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening and procedures of Shenzhen BGI Genomics Co., Ltd.'s 2022 first extraordinary general meeting of shareholders. It details the legality of the meeting's notice, attendance, voting procedures, and results. The document does not contain financial statements or performance data but focuses on the legal compliance of the shareholders' meeting process and voting outcomes. This type of document is related to the declaration of voting results and voting rights announcements from a shareholders' meeting. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (5717 characters) and content confirm it is not a brief announcement but a detailed legal opinion on the meeting and voting results, fitting the DVA category with high confidence.
2022-02-11 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.